Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Enterprise Value (2021 - 2025)

ARS Pharmaceuticals' Enterprise Value history spans 5 years, with the latest figure at -$245.0 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 21.98% year-over-year to -$245.0 million; the TTM value through Dec 2025 reached -$245.0 million, up 21.98%, while the annual FY2025 figure was -$245.0 million, 21.98% up from the prior year.
  • Enterprise Value for Q4 2025 was -$245.0 million at ARS Pharmaceuticals, up from -$288.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$60.1 million in Q4 2021 and bottomed at -$374.2 million in Q1 2021.
  • The 5-year median for Enterprise Value is -$255.9 million (2022), against an average of -$257.2 million.
  • The largest YoY upside for Enterprise Value was 32.16% in 2022 against a maximum downside of 356.82% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$60.1 million in 2021, then tumbled by 356.82% to -$274.4 million in 2022, then grew by 16.77% to -$228.4 million in 2023, then tumbled by 37.51% to -$314.0 million in 2024, then increased by 21.98% to -$245.0 million in 2025.
  • Per Business Quant, the three most recent readings for SPRY's Enterprise Value are -$245.0 million (Q4 2025), -$288.2 million (Q3 2025), and -$240.1 million (Q2 2025).